These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20045317)

  • 1. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
    Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
    Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
    Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
    Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
    Lu A; Zhang J; Yin X; Luo X; Jiang H
    Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
    Saxena S; Chaudhaery SS; Varshney K; Saxena AK
    SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
    Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
    J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
    Rao PN; Chen QH; Knaus EE
    J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
    Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel acyl coenzyme a: cholesterol acyltransferase inhibitors: pharmacophore-based virtual screening, synthesis and pharmacology.
    Chhabria MT; Brahmkshatriya PS; Mahajan BM; Darji UB; Shah GB
    Chem Biol Drug Des; 2012 Jul; 80(1):106-13. PubMed ID: 22429570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
    Krovat EM; Langer T
    J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach.
    Charlier C; Hénichart JP; Durant F; Wouters J
    J Med Chem; 2006 Jan; 49(1):186-95. PubMed ID: 16392803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
    Vadivelan S; Sinha BN; Rambabu G; Boppana K; Jagarlapudi SA
    J Mol Graph Model; 2008 Feb; 26(6):935-46. PubMed ID: 17707666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
    Adane L; Bharatam PV; Sharma V
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques.
    Gupta S; Fallarero A; Järvinen P; Karlsson D; Johnson MS; Vuorela PM; Mohan CG
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1105-12. PubMed ID: 21273074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.
    Ravikumar M; Pavan S; Bairy S; Pramod AB; Sumakanth M; Kishore M; Sumithra T
    Chem Biol Drug Des; 2008 Jul; 72(1):79-90. PubMed ID: 18498326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors.
    Bharatham N; Bharatham K; Lee KW
    J Mol Graph Model; 2007 Mar; 25(6):813-23. PubMed ID: 16996282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
    Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
    J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors.
    Deng XQ; Wang HY; Zhao YL; Xiang ML; Jiang PD; Cao ZX; Zheng YZ; Luo SD; Yu LT; Wei YQ; Yang SY
    Chem Biol Drug Des; 2008 Jun; 71(6):533-9. PubMed ID: 18410307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.